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Summary
Several candidate gene studies on the metabolic syndrome (MetS) have been
conducted. However, for most single nucleotide polymorphisms (SNPs) no sys-
tematic review on their association with MetS exists. A systematic electronic
literature search was conducted until the 2nd of June 2010, using HuGE Navi-
gator. English language articles were selected. Only genes of which at least one
SNP–MetS association was studied in an accumulative total population 4000
subjects were included. Meta-analyses were conducted on SNPs with three or
more studies available in a generally healthy population. In total 88 studies on 25
genes were reviewed. Additionally, for nine SNPs in seven genes (GNB3, PPARG,
TCF7L2, APOA5, APOC3, APOE, CETP) a meta-analysis was conducted. The
minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5),
T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were
more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP)
was less prevalent in subjects with the MetS. After having systematically reviewed
the most studied SNP–MetS associations, we found evidence for an associa-
tion with the MetS for eight SNPs, mostly located in genes involved in lipid
metabolism.
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Introduction
The metabolic syndrome (MetS) is a common multi-
component condition including abdominal obesity, dyslipi-
daemia, hypertension and hyperglycaemia. It is associated
with an increased risk of coronary heart disease (CHD) and
type 2 diabetes (T2D). The prevalence of MetS, which is
currently around 30%, is rising worldwide (1).
Heritability estimates for MetS range from 10% to 30%
(2–4), indicating that MetS is partly heritable. Knowledge
of the exact genetic factors underlying MetS development
may help to explain why the features of MetS frequently
co-occur within one individual. In order to detect genes
underlying MetS development several candidate gene
studies have been performed with inconsistent results.
However, no systematic review has been conducted to date,
and thus no clear overview of the available evidence on the
genetics of the MetS exists. Therefore, the objective of this
paper is to systematically review the studies on single nucle-
otide polymorphisms (SNPs) and MetS, and where possible
to summarize the results using meta-analyses.
Methods
Search strategy
An electronic literature search was conducted using HuGE
Navigator. HuGE Navigator is a database of published
population-based epidemiologic studies of human genes
extracted and curated from PubMed since 2001 (5).
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Previous validations on selected gene-disease associations
showed that HuGE Navigator was equally sensitive, but
more specific than PubMed (6).
For the Huge Navigator search, the search term ‘meta-
bolic syndrome ¥ [Text MesH]’ was used. This search
retrieved articles on the association between MetS and any
genetic variant. The latest search was undertaken on 2nd
of June 2010. As HuGE Navigator only retrieves articles
published since 2001, an additional PubMed search was
done. For the PubMed search, the search term ‘metabolic
syndrome ¥ [Text + MesH] with limits on publication date
from 1990/1/1 to 2001/12/31’ was used.
Eligibility criteria
Articles were included when they contained MetS as
outcome and were: published in English; original research
articles; conducted in humans; and testing for SNP main
effects. All existing definitions of MetS (Table S1) were
eligible as study outcome.
Genes were included if two or more articles were
retrieved on the same gene, and at least for one of the SNPs
in this gene the accumulative total study population was
4000 subjects. A study with 4000 subjects has a power of
80% to detect an OR 0.8 or an OR 1.2, assuming a
significance level of 0.05, a MetS prevalence of 30% and a
minor allele frequency (MAF) of 0.25. An exception was
made for the ADIPOQ gene, which has been related to
MetS in linkage studies (7). The ADIPOQ G276T
(rs1501299) polymorphism was studied in an accumulative
total population of 3865 subjects only. However, because
the MAF of this SNP was 0.30 instead of 0.25, the power
to detect an association was 90%. For other SNPs investi-
gated in 3000–3999 subjects either the MAF was too low
to obtain sufficient power, or the prior evidence substanti-
ating an association with MetS was weak.
Included studies were eligible for inclusion in the meta-
analyses if they had a cross-sectional or case–control
design, and if the crude genotype distribution according to
MetS status was available. If the genotype distribution
could not be extracted from the original research article,
investigators were contacted via email. Meta-analyses were
carried out for SNPs with both three or more eligible
studies available in a generally healthy population and with
inconsistent study outcomes.
Data extraction
Data extraction was conducted by one author (CMP). For
quality control, data were extracted by two of the other
authors (JMAB, ER) for 10% of the entered papers. Only
minor discrepancies were found. For each article the fol-
lowing information was extracted: authors, publication
year, sample size, number of MetS cases, ethnicity, health
status of the population (e.g. CHD or T2D patients),
study design, mean age, percentage men, crude genotype
distribution by MetS status, odds ratio and the reported
measure of variance. For the selected genes all SNP–MetS
associations published, independent of sample size, were
extracted. If results were given for multiple MetS defini-
tions, results for the definition of the NCEP ATPIII, which
is the most common definition, were extracted. If results
were presented separately for men and women an aggregate
effect measure was calculated where possible.
Data analyses
For SNPs located in the same gene we checked the corre-
lation coefficients according to HapMap. If SNPs had a
correlation 0.8 we mentioned this in the results.
For SNPs included in the meta-analyses, ORs of indi-
vidual studies were recalculated from the available
genotype distributions according to an allelic model. After-
wards, combined ORs were calculated using random effect
models and forest plots were drawn. Heterogeneity was
investigated by the I2 statistic. Roughly, I2 values of 25%,
50% and 75% can be regarded as low, moderate and high
heterogeneity (8). The following sources of heterogeneity
were explored by meta-regression: health status of the
population (e.g. CHD or T2D patients), gender, age, MetS
definition, study design and ethnicity. In some cases too few
studies were available to conduct meta-regression with
stata. In those cases sensitivity analyses were performed.
Funnel plots, Egger’s and Begg’s tests were used to check
for publication bias. stata 11 (StataCorp LP, Collega
Station, TX, USA) was used to perform all analyses.
Results
Our literature search yielded 104 articles identified through
PubMed and 465 articles identified through Huge Naviga-
tor (Fig. 1). None of the studies identified through PubMed
was eligible, while 186 identified through Huge Navigator
were. Of the eligible papers, 51 were excluded because <2
articles were published on the same gene, and 48 were
excluded because all SNPs in the gene described in the
article were studied in <4000 subjects. Finally, 87 articles
on 25 genes were included in this review. In these 87
articles 88 studies were described.
The majority of the studies were cross-sectional studies
(n = 73; 83%). Of the remaining studies, 11 were case–
control studies, 3 were family studies and 1 was a prospec-
tive study. Most studies were either conducted in subjects
of Caucasian (n = 56; 64%) or Asian origin (n = 21; 24%).
The average prevalence of MetS across all studies was
30%. In 75% (n = 66) of the studies MetS was defined
according to the criteria of the NCEP ATP III.
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Meta-analyses were carried out for those SNPs with
three or more eligible studies available in a generally
healthy population, which included 37 studies (7,9–43) on
nine SNPs located in seven genes (GNB3, PPARG,
TCF7L2, APOA5, APOC3, APOE, CETP). In none of the
meta-analyses the Egger’s test, the Begg’s test or the funnel
plots could indicate the presence of publication bias.
First, we will describe the association between MetS and
those genes with sufficient data for meta-analyses. Second,
we will describe the remaining SNP–MetS associations in a
narrative review. In Table 1, an overview is provided of all
genes studied, the pathways they are involved in and the
results of the meta-analyses. Detailed information on all
studies is available in Table S2.
Results of the meta-analyses
PPARG
PPARG is a nuclear receptor involved in glucose and fatty
acid metabolism (22). The Pro12Ala (rs1801282) polymor-
phism of the PPARG gene has been consistently associated
with T2D (44,45). However, of the 16 studies investigating
the association between Pro12Ala (rs1801282) and MetS
(7,11–18,20–22,46,47), most showed no effect (7,9,11–
22,46,47). This is confirmed by our meta-analysis among
13 studies (7,9,11–20,22) (pooled OR of Ala vs. Pro 1.08;
95% 0.93–1.24, I2 = 48.3%) (Fig. 2). Meta-regression
revealed that population characteristics such as ethnicity
and health status could not explain the moderate hetero-
geneity present in this meta-analysis (Table S3). Interest-
ingly, although the 12Pro allele is associated with increased
risk of T2D and insulin resistance independent of body
mass index (BMI) (44), from the meta-analysis it can be
concluded that if any effect on MetS exists, 12Ala is the risk
allele. As the 12Ala genotype has been associated with BMI
in a meta-analysis among Caucasian subjects (44), this
effect could possibly be mediated by BMI.
The association between C1431T (rs3856806), another
well-known PPARG polymorphism, and MetS, has been
investigated in six cross-sectional studies (22–24,26,28,30)
and one family study (47). In the family study, conducted
among 423 Chinese subjects, the prevalence of the 1431T
allele was lowest in subjects with MetS. However, in our
meta-analysis of the six cross-sectional studies (22–
24,26,28,30) there was no association between C1431T
(rs3856806) and MetS (pooled OR of T vs. C 0.97, 95% CI
0.86–1.11, I2 = 0%) (Fig. 3).
Interestingly, although both the 12Ala and the 1431C
allele did not seem to increase MetS risk significantly in our
meta-analyses, a haplotype containing the same alleles was
associated with an increased prevalence of MetS in a cross-
sectional study among 1115 French subjects (22). Other
SNPs in the PPARG gene have not been associated with
MetS (27,48).
Figure 1 Literature search results. SNP, single nucleotide polymorphism.
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Table 1 Summary of the reviewed SNPs in relation to metabolic syndrome
Gene – SNPs Pathways involved Results
Weight
regulation
Glucose
metabolism
Lipid
metabolism
Inflammation Blood
pressure
Meta-analyses Pooled OR I2 (%)
PPARG
Pro12Ala (rs1801281) ¥ ¥ ¥ 1.08 (95% CI: 0.93–1.24) 48.3
C134T (rs3856806) 0.97 (95% CI: 0.86–1.11) 0
TCF7L2
rs7903146 ¥ 1.18 (95% CI 1.04–1.34) 25.6
APOA5
T113C (rs662799) ¥ 1.24 (95% CI 1.10–1.41) 47.7
C56G (rs3135506) 1.26 (95% CI 1.09–1.47) 0
APOC3
C482T (rs2854117) ¥ 1.57 (95% CI 1.00–2.48) 90.5
C455T (rs2854116) NA
APOE
e2/e3/e4 (e2/- vs. e3/e3) ¥ 0.91 (95% CI 0.70–1.18) 7.5
e2/e3/e4 (e4/- vs. e3/e3) 1.61 (95% CI 0.87–2.97) 88.3
CETP
Taq-1B (rs708272) ¥ 0.93 (95% CI 0.80–1.90) 59.8
0.89 (95% CI 0.80–0.97)* 4.4
GNB3
C825T (rs5433) ¥ ¥ ¥ 1.03 (95% CI 0.94–1.12) 0
FTO
rs9939609 ¥ 1.17 (95% CI 1.10–1.25) (63) 0
Narrative review Evidence level
UCP1 ¥ (-)
UCP2 ¥ (-)
LEPR ¥ ¥ ¥ (-)
ADIPOQ
G276T (rs1501299) ¥ ¥ ¥ (-)
IL6
174G>C (rs1800795) ¥ (+)
RETN
420C>G (rs1862513) ¥ ¥ (-)
LMNA
H566H (rs4641) ¥ ¥ ¥ (-)
ADRB2
Arg16Gly (rs1042713) ¥ ¥ ¥ (-)
Gln27Gln (rs1042714) (-)
ADRB3
Trp64Arg (rs4994) ¥ ¥ ¥ (-)
PPARD
87T>C (rs2016520) ¥ ¥ (-)
PPARGC1A
Gly482Ser (rs8192678) ¥ ¥ (-)
Thr394Thr (rs3755863) (-)
FABP2
Ala54Thr (rs179883) ¥ ¥ (-)
CAPN10
UCSNP43 (rs3792267) ¥ (-)
IRS1
Gly927Arg (rs1801278) ¥ (-)
ENPP1
K21Q (rs1044498) ¥ (-)
GCK
30G>A (rs1799884) ¥ (-)
KCNJ11
E23K (rs5219) ¥ (-)
(+), sufficient evidence for an association based on the narrative review; (-), insufficient evidence for an association based on the narrative review.
*Results of a sensitivity analysis in non-patients.
NA, not available; SNP, single nucleotide polymorphism.
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TCF7L2
The TCF7L2 gene is involved in Wnt signalling and insulin
secretion (49). The T allele of the rs7903146 polymor-
phism in the TCF7L2 gene increases the risk of T2D (50).
The T allele also increased MetS risk in our meta-analysis
of five studies (pooled OR 1.18, 95% CI 1.04–1.34)
(Fig. 4) (23–27). The heterogeneity between studies was
low (I2 = 25.6%), and decreased to 0% in a sensitivity
analysis among generally healthy subjects (24–27). The
pooled OR increased to 1.29 (95% CI 1.10–1.36).
Although both Begg’s (P = 0.01) and Egger’s tests
(P = 0.008) were significant, no publication bias was
present, as the largest studies had the largest effect. One
expects that in case of publication bias, the smallest
Figure 2 Meta-analysis on the association between the PPARG Pro12Ala (rs1801282) polymorphism and the metabolic syndrome; heterogeneity
I2 = 48.3%; MAF Caucasian 0.06–0.17; MAF Asian 0.05–0.13; MAF mixed population 0.09; MAF, minor allele frequency; OR, odds ratio.
Figure 3 Meta-analysis on the association
between the PPARG C1431T (rs3856806)
polymorphism and the metabolic syndrome;
heterogeneity I2 = 0%; MAF Asian 0.14–0.30;
Caucasian 0.08–0.15; MAF, minor allele
frequency; OR, odds ratio.
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studies would show the highest ORs (51,52). A prospec-
tive study among 16 143 Swedes confirmed the results of
our meta-analysis. In this prospective study the OR for
developing MetS in 23 years was 1.10 (95% CI 1.04–
1.17) (46).
As expected results for the rs12255372 polymorphism
(24–26) were similar as those of the completely correlated
rs7903146 polymorphism (r2 = 1 HapMap CEU). Further-
more, in one study among obese hypertensive patients the
TCF7L2 copy number variation, DG10S478X, was asso-
ciated with MetS (23).
APOA5
APOA5 reduces plasma triglyceride levels by stimulating
the hydrolysis of triglycerides through the activation of
lipoprotein lipase and by inhibiting very low density lipo-
proteins production (53). The C allele of the T1131C
(rs662799) polymorphism in the APOA5 gene is associated
with higher triglycerides and reduces high-density lipo-
protein (HDL) cholesterol levels (54–56). The T1131C
(rs662799) polymorphism, or genetic variants highly cor-
related with the T1131C (rs662799) polymorphism, were
significantly associated with MetS in all (21,28–34,54–56),
but three studies (28,31,55). Accordingly, in our meta-
analysis among nine of these studies (21,28–34) the C allele
of the T1131C (rs662799) polymorphism increased MetS
risks (pooled OR 1.24, 95% CI 1.10–1.41) (Fig. 5). Meta-
regression analysis revealed that the moderate heterogene-
ity (I2 = 47.7%) present could be explained by population
characteristics such as sex and ethnicity (Table S4). There-
fore, we performed a sensitivity analysis in Caucasian
subjects only. The OR in this sensitivity analysis was some-
what lower (pooled OR C vs. T 1.20, 95% CI 1.02–1.41,
I2 = 19.0%).
Another APOA5 polymorphism that has been fre-
quently investigated in relation to MetS is the C56G
(rs3135506) polymorphism. The meta-analysis included
five studies (28,31,32,34) and showed that the G allele
of the C56G (rs3135506) polymorphism increased MetS
risk (pooled OR 1.26, 95% CI 1.09–1.47, I2 = 0%)
(Fig. 6). However, the C56G (rs3135506) polymorphism
was not associated with MetS in a study among 2417
Japanese, which could not be included in the meta-
analysis, because the genotype distribution could not be
obtained (54).
Three other APOA5 polymorphisms, all not correlated
with one of the polymorphisms discussed above, have also
been investigated in relation to MetS (29,31,54). Two of
these polymorphisms, 12238T>C (rs625524) (29) and
Gly185Cys (rs2075291) (54), were associated with MetS,
in one single study.
APOC3
APOC3 increases plasma triglycerides levels, by the inhibi-
tion of lipoprotein lipase activity and by the interference
with ApoE-mediated uptake of triglycerides (48,57). The
minor 482T allele of the APOC3 C482T (rs2854117) poly-
morphism is associated with increased triglyceride levels
(58). The same allele also increased MetS risk in four
(18,34,35,48) out of five studies (18,29,34,35,48). Our
meta-analysis among the four studies with genotype distri-
butions available (18,29,34,35) confirmed that the 482T
allele increased MetS risk (pooled OR 1.57, 95% CI 1.00–
2.48) (Fig. 7). However, although the direction of the effect
was the same for most studies, the heterogeneity between
studies was high (I2 = 90.5%). Both the heterogeneity and
the OR were slightly lower among cross-sectional studies
(OR 1.24, 95% CI 0.90–2.01, I2 = 78.2%) (29,35) and
Figure 4 Meta-analysis on the association
between the TCF7L2 rs7903146 polymorphism
and the metabolic syndrome; heterogeneity
I2 = 25.6%; MAF Caucasian 0.28–0.35; MAF
Arabic 0.39; MAF, minor allele frequency;
OR, odds ratio.
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studies in Caucasian subjects (OR 1.16, 95% CI 0.79–1.70,
I2 = 84.9%) (29,34,35).
As expected results for the C455T (rs2854116) poly-
morphism (18,34,35,48,59) were similar to those of the
highly correlated C482T (rs2854117) polymorphism
(r2 = 0.97 HapMaP CEU) (35). On the contrary, for
APOC3 1100C>T (15) and APOC3 SstI (20,29) no asso-
ciation with MetS could be detected.
APOE
Apolipoprotein-E (APOE) has an important function in the
clearance of chylomicron remnants and very low density
lipoproteins from plasma. Three APOE isoforms encoded
by the e2/e3/e4 haplotype exist. The e3 isoform is the most
prevalent isoform. In comparison with the e3 isoform,
the e2 isoform decreases cholesterol levels and increases
triglyceride levels, whereas the e4 isoform increases both
Figure 5 Meta-analysis on the association between the APOA5 T1131C (rs662799) polymorphism and the metabolic syndrome; heterogeneity
I2 = 47.7%; MAF Arabic 0.13; MAF Asian 0.30–0.31; MAF Caucasian 0.06–0.08; MAF Hispanic 0.14; MAF, minor allele frequency; OR, odds ratio.
Figure 6 Meta-analysis on the association
between the APOA5 C56G (rs3135506)
polymorphism and the metabolic syndrome;
heterogeneity I2 = 0%; MAF Arabic 0.05; MAF
Caucasian 0.06–0.09; MAF Hispanic 0.10;
MAF, minor allele frequency; OR, odds ratio.
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cholesterol and triglyceride levels (60). In our meta-analysis
among five studies (18,36–38,43) the e2/- genotype (e2/
e3 + e2/e2) none significantly decreased MetS risk (pooled
OR e2/- vs. e3/e3 0.91; 95% CI 0.70–1.18, I2 = 7.5%)
whereas the e4/- genotype (e4/e4 + e4/e3) tended to
increase MetS risk (pooled OR e4/- vs. e3/e3 1.61, 95% CI
0.87–2.97, I2 = 88.3%) (Fig. 8). The fact that four out
of five studies were conducted in subjects of different
ethnicity may explain the high heterogeneity (I2 = 88.3%)
observed for the e4/- genotype.
In two studies the effect of individual SNPs in the APOE
gene instead of the effect of the e2/e3/e4 haplotype was
investigated. In a study among 1788 Japanese (21), in
which three SNPs of the APOE gene had been genotyped,
the Arg158Cys (rs7412) polymorphisms, which is part of
the e2/e3/e4 haplotype, was associated with MetS.
However, this association could not be replicated in 305
Caucasian coronary artery disease patients (20).
CETP
The cholesteryl ester transfer protein (CETP) plays an
import role in reverse cholesterol transport. The B2 allele
of the CETP Taq-1B (rs708272) polymorphism increases
HDL cholesterol levels and decreases triglyceride levels and
CETP activity (61). In our meta-analysis including four
studies (36,39–41), the B2 allele tended to decrease MetS
risk (pooled OR 0.93, 95% 0.80–1.09, I2 = 59.8%.)
(Fig. 9). When we excluded the study of Ranjith et al. (36)
among 592 patients with acute MI from our meta-analysis
the heterogeneity decreased (I2 = 4.4%), and the OR
became significant (pooled OR B2 vs. B1 0.89, 95% CI
0.80–0.97). The study among 1788 Japanese, which could
not be included in the meta-analysis, showed no association
between the Taq-1B (rs708272) polymorphism and MetS
(54). Furthermore, in studies on other polymorphisms in
the CETP gene, no associations with MetS were observed
(20,21,54).
FTO
Studies in humans and rodents suggest that FTO regulates
food intake and effects the lypolytic activity in adipose
tissue (62). The A allele of the rs9939609 polymorphism
in the FTO gene has been associated with increased BMI
and T2D risk in multiple genome wide association
studies (GWAS) (63). The A allele of the rs9939609 also
increased MetS prevalence in a large meta-analysis among
12555 European subjects (OR per A allele 1.17; 95% CI
1.10–1.25, P = 3.0 ¥ 10-6) (63) and in a smaller meta-
analysis among 2112 subjects of mixed ethnicity
(AA + AT vs. TT OR 1.26; 95% CI 1.02–1.57) (64). ORs
of the individual studies included in the meta-analyses
ranged from 1.10 to 1.44. In line with these results, the
OR per A allele for developing MetS in 23 years was 1.08
(95% CI 1.02–1.14) in a large prospective study among
16 143 non-diabetic Swedes (46). Furthermore, the
rs1421085 polymorphism, which is highly correlated with
the rs9939609 polymorphism (r2 = 0.93), was associated
with MetS in two independent studies (65,66). On the
contrary, rs9939609 and two other highly correlated
polymorphisms were not associated with MetS in a study
among 1488 Japanese (67).
GNB3
The GNB3 gene is involved in G-protein signal transduc-
tion. The C825T (rs5433) polymorphism in the GNB3
gene has been associated with obesity, hypertension, dys-
lipidaemia and T2D, which are all features of MetS
(10,42). However, although in one study the C825T
Figure 7 Meta-analysis on the association
between the APOC3 C482T (rs2854117)
polymorphism and the metabolic syndrome;
heterogeneity I2 = 90.5%; MAF mixed
population 0.24; MAF Caucasian (excluding
Oji Cree aboriginals33) 0.21–0.27; MAF Oji
Cree aboriginals33 0.43–0.44; MAF, minor
allele frequency; OR, odds ratio.
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Figure 8 (a) Meta-analysis on the association between the APOE e2/e3/e4 haplotype and the metabolic syndrome; heterogeneity I2 = 7.5%; frequency
e2 Arabic 0.12; frequency e2 Asian 0.05; frequency e2 Caucasian 0.06–0.09; frequency e2 mixed 0.05; OR, odds ratio; (b) meta-analysis on the
association between the APOE e2/e3/e4 haplotype and the metabolic syndrome; heterogeneity I2 = 88.3%; frequency e4 Arabic 0.07; frequency e4
Asian 0.09; frequency e4 Caucasian 0.08–0.09; frequency e4 mixed 0.20; OR, odds ratio.
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(rs5433) polymorphism was associated with MetS in Oji
Cree women (35), other studies could not replicate these
results (10,18,21,42). Also, our meta-analysis of four
studies (10,18,35,42) (Fig. 10) could not demonstrate an
association between the C825T (rs5433) polymorphism
and MetS (pooled OR of 825T vs. C 1.03, 95% CI 0.94–
1.12, I2 = 0). In one study, among 2417 Japanese, the asso-
ciation with the GNB3 1429C>T (rs5446) polymorphism
was investigated (54). Also this polymorphism was not
associated with MetS.
Narrative review of associations with metabolic
syndrome for single nucleotide polymorphisms not
eligible for meta-analysis
In this narrative review we describe SNPs that were not
eligible for meta-analysis because they have been studied in
too few studies with generally healthy subjects. Detailed
information about these SNPs can be found in Table S2i–y.
Of all SNPs, the strongest evidence for an association
with MetS was found for the IL6 174G>C (rs1800795)
Figure 9 Meta-analysis on the association between the CETP Taq-1B (rs708272) polymorphism and the metabolic syndrome; heterogeneity
I2 = 59.8%; MAF Arabic 0.43; MAF Asian 0.48; MAF Caucasian 0.41–0.43; MAF, minor allele frequency; OR, odds ratio.
Figure 10 Meta-analysis on the association
between the GNB3 C825T (rs5433) and the
metabolic syndrome; heterogeneity I2 = 0%;
MAF mixed 0.34; MAF Caucasian (excluding
Oji Cree aboriginals33) 0.31–0.34; MAF Oji
Cree aboriginals33 0.46–0.49; MAF, minor
allele frequency; OR, odds ratio.
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promoter polymorphism. IL-6 is a cytokine with a broad
range of effects, e.g. it is the primary determinant of hepatic
CRP secretion (68). Elevated plasma IL-6 levels are associ-
ated with T2D and CHD, both end stages of MetS (68).
The association between the IL6 174G>C (rs1800795)
promoter polymorphism and MetS was significant in three
(20,68,69) out of four (20,68–70) studies. In three studies
the 174C allele increased MetS risk (68–70), while in a
fourth study the direction of the association was not
reported (20). In most studies on inflammatory SNPs other
than IL6 174G>C (rs1800795), such as SNPs in RETN
(21,71,72) and ADIPOQ (54–58,73,74), no association
with MetS was found. Especially for ADIPOQ this was
remarkable. The ADIPOQ gene encodes for adiponectin.
Lower plasma adiponectin concentrations have been asso-
ciated with several features of MetS including insulin resis-
tance (75). Furthermore, in a linkage study the ADIPOQ
locus, 3q27, was associated with MetS (76). However, in
most studies the ADIPOQ G276T (rs1501299) polymor-
phism was not associated with MetS (75,77–79). Further-
more, in the single study in which an effect was shown for
ADIPOQ G276T (rs1501299) (80), this effect was oppo-
site to the effect expected based on the association of
ADIPOQ G276T (rs1501299) with adiponectin and
insulin sensitivity (81). The ADIPOQ G276T (rs1501299)
polymorphism was not the only SNP in which, despite
strong prior evidence for possible involvement of the gene
in MetS development, an association with MetS seemed
absent. Also, no association with MetS seemed to exist for
SNPs in the LMNA (82–85) gene, while the LMNA gene is
associated with lipodystrophy, a syndrome that shares
many features with MetS (82).
Involvement of a gene in multiple MetS pathways did not
guarantee an association for SNPs in this gene with MetS.
The evidence for an association with MetS was weak for
SNPs in the ADRB2 (20,21,46,86) and ADRB3 (21,46,87–
89) gene, genes involved in glucose metabolism, lipid
metabolism and blood pressure regulation (86), SNPs in the
LEPR gene (54,90,91), which is involved in body weight
regulation, fatty acid oxidation and glucose metabolism
(92); SNPs in the PPARD gene (21,93,94), which regulates
both glucose and energy metabolism (94); and SNPs in the
PPARGC1A gene (11,21,46,95), which is involved in lipid
and glucose metabolism (95). However, for the Ala54Thr
(rs1799883) SNP (18,35,48,96–98) in the FABP2 gene,
which is involved in both fatty acid and glucose metabolism
(96,97), some evidence for an association with MetS exists.
In the majority of studies (18,35,96–98), most of which
were conducted in patient populations (48,96–98), the
Thr54 allele increased MetS risk, although in most
studies the association was not statistically significant
(18,35,96,98). For all other SNPs reviewed, either located
in genes involved in energy metabolism (UCP1 and UCP2
(11,21,46,54,99–101)) or in genes involved in glucose
metabolism (CAPN10 (21,46,102–105), IRS1 (15,21,46),
ENPP1 (21,46,106–108), GCK (21,109) and KCNJ11
(15,21,46)) the evidence for an association with MetS was
not substantial.
Discussion
In this systematic review we described the most studied
SNPs in relation to MetS. The overall results suggest an
association with MetS for SNPs in the FTO, TCFL72, IL6,
APOA5, APOC3 and CETP genes.
The FTO rs9939609 and the TCF7L2 rs7903146 poly-
morphism are the top hits of GWAS on respectively BMI
(110) and T2D (111). The TCF7L2 rs7903146 polymor-
phism influences insulin secretion, and to a lesser extent
this SNP also affects insulin resistance (112). The 174C
allele of the IL6 174G>C (rs1800795) polymorphism
increased MetS risk in three (20,68,69) out of four studies
(20,68–70). In line with the effect on MetS the 174CC
genotype tended to increase BMI and IL6 levels (113), both
MetS-associated features, in meta-analysis on 15 and 17
studies, respectively. Accordingly, in another meta-analysis
on seven studies the 174CC genotype also tended to
increase CHD risk, an end stage of MetS (114). However,
contrary to the effect on MetS, the 174CC genotype sig-
nificantly decreased glucose levels in a meta-analysis on
seven studies (113). The other SNPs that were associated
with MetS, the T1131C APOA5 (rs662799) (31), the
C56G APOA5 (rs3135506) (31), the C455T (rs2854116)
APOC3, the C482T (rs2854117) APOC3 (58) and the
Taq-1B (rs708272) CETP (61) polymorphisms are all
associated with hypertriglyceridaemia. Furthermore, the
C482T (rs2854117) polymorphism, which is located in
the insulin response element of the APOC3 gene promoter,
has also been associated with insulin and glucose levels
(57,115).
Focussing on combined phenotypes, like MetS, may lead
to the discovery of new SNPs that would not have been
found when studying the phenotypes separately. The fact
that the study of combined phenotypes may lead to the
discovery of new risk loci is nicely illustrated by a recent
GWAS on Crohn’s and Celiac disease, where the focus on
risk loci shared between Crohn’s and Celiac disease leads to
the discovery of six new risk loci (116). All SNPs included
in this review that were associated with MetS were also
strongly associated with an individual feature of MetS. Up
till now no SNP has been found, which has only a minor
effect on individual MetS features, but which does affect
the clustering of the different features. Nevertheless, such a
SNP may still be discovered. Interestingly, we observed that
although all SNPs associated with MetS were associated
with an individual MetS feature the reverse is not always
true. For example, both PPARG Pro12Ala (rs1801282)
and TCF7L2 rs7903146 are associated with hyperglycae-
962 Genetics of metabolic syndrome C. M. Povel et al. obesity reviews
© 2011 The Authors
obesity reviews © 2011 International Association for the Study of Obesity 12, 952–967
mia. However, only TCF7L2 rs7903146 and not PPARG
Pro12Ala (rs1801282) seemed to be associated with MetS.
This subdivision of on the one hand SNPs that are associ-
ated with one MetS feature only, and on the other hand
SNPs that are associated with multiple MetS features, and
thus also associated with MetS, may facilitate the discovery
of pathways responsible for the clustering of MetS features.
Interestingly, although disturbances in glucose metabo-
lism (1), weight regulation (1) and inflammation (117) all
three have been proposed to initiate MetS, most SNPs
associated with MetS are located in genes involved in lipid
metabolism. The associations of these SNPs in the CETP,
APOC3 and APOA5 genes with the MetS may be mediated
by hypertriglyceridaemia. Accumulation of triglycerides in
the muscles may stimulate the development of insulin resis-
tance (118). Furthermore, dysfunctioning of the APOA5
and APOC3 genes increases free fatty acid levels (57,119),
which in turn may stimulate development of MetS features,
such as dyslipidaemia, overweight, insulin resistance,
hypertension or inflammation (118). Alternatively, the
overrepresentation of SNPs in lipid metabolism may be
caused by the stress put on lipid metabolism in MetS defi-
nition. In the most common MetS definitions, the NCEP
ATP III and the IDF definition, a disturbed lipid metabo-
lism is characterized by two MetS features, i.e. low HDL
cholesterol levels and increased triglyceride levels, whereas
disturbances in the other mechanisms such as weight regu-
lation are all only characterized by one MetS feature.
In this review we have focussed on SNP–MetS associa-
tions, which have been investigated in at least two studies.
Consequently, significant SNP–MetS associations that have
not been researched yet or that have only been researched
in one study were not described. One of the best ways to
test a large number of not investigated SNP–MetS associa-
tions is to conduct a GWAS. Unfortunately, to the best of
our knowledge, such a GWAS has not been conducted yet.
Strength of this review is the unbiased way in which we
have summarized results of the available studies on SNP–
MetS associations. For all genes described, at least one
SNP–MetS association was investigated in an accumulative
total population across all published studies 4000 sub-
jects. The number of 4000 subjects allowed us to detect
SNP–MetS associations of moderate effect size (OR 0.8
or an OR 1.2). Therefore, we may have missed associa-
tions of smaller effect size. For example, the pooled OR of
0.90 for the APOE e2e3e4 haplotype was not statistically
significant in our meta-analysis. Population characteristics,
such as ethnicity and health status of the study population,
differed between the studies included in this review. Despite
these differences, study outcomes were homogeneous for
some SNPs, e.g. the GNB3 C825T (rs5433) and PPARG
C1431T (rs3856806) polymorphism. However, for other
SNPs these differences could explain the observed hetero-
geneity in study outcomes. For example, ethnicity
explained nearly all heterogeneity present in the meta-
analysis on APOA5 T1131C (rs662799). Furthermore,
heterogeneity decreased and the OR increased, if studies in
patient populations were excluded from the meta-analyses
on the TCF7L2 rs7903146 and the CETP Taq-1B
(rs708272) polymorphisms. In two meta-analyses, on the
APOC3 C482T (rs2854117) polymorphism and APOE
e2e3e4 haplotype, a high unexplained heterogeneity was
present. Especially for these genetic variants it will be valu-
able to conduct an updated meta-analysis stratified for
several subgroups, if more studies become available. The
Egger’s and Begg’s tests did not indicate that in any of the
meta-analyses publication bias was present. However, both
tests have a low power unless a large number of studies
(n  25) are analysed (51,52). As our meta-analyses were
conducted among a smaller number of studies, we can not
rule out the possibility that publication bias is present
anyway.
In conclusion, we found evidence for an association with
MetS for eight SNPs. All of these SNPs were also associated
with an individual MetS feature, most of them with dys-
lipidaemia. This suggests that lipid metabolism plays a
central role in MetS development.
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